Drug Trial Radar · NCT01446679
Special Drug Use-Results Survey of Lipitor Tablets
Last checked: Nov 19, 2026Latest source record: Feb 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24,050
Actual
Start
Sep 2010
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Oct 5, 2011
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve the category-specific targeted lipid levels.
Conditions
- Hypercholesterolemia
Interventions
atrovastatinDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in plasma LDL-C concentrationTime frame: 0, 4, 12 and 24 week
- Change in rate of achievement of the category-specific target LDL-C levelTime frame: 0, 4, 12 and 24 week
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Chūbu, Japan
Site not named
Chugoku, Japan
Site not named
Hokkaido, Japan
Site not named
Kansai, Japan
Site not named
Kantou, Japan
Site not named
Kyushu, Japan
Site not named
Shikoku, Japan
Site not named
Tōhoku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.